Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia

Authors:

Abstract
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder that predominantly affects infants and young children. Hematopoietic stem cell transplantation (HSCT) is standard of care, but post-HSCT relapse is common, highlighting the need for innovative therapies. While adoptive immunotherapy with chimeric antigen receptor (CAR) T cells has improved outcomes for patients with advanced lymphoid malignancies, it has not been comprehensively evaluated in JMML. In the present study, we use bulk and single-cell RNA sequencing, mass spectrometry, and flow cytometry to identify overexpression of CLL-1 (encoded by CLEC12A) on the cell surface of cells from patients with JMML. We develop immunotherapy with CLL-1 CAR T cells (CLL1CART) for preclinical testing and report in vitro and in vivo anti-leukemia activity. Notably, CLL1CART reduce the number of leukemic stem cells and serial transplantability in vivo. These preclinical data support the development and clinical investigation of CLL-1-targeting immunotherapy in children with relapsed/refractory JMML.
Funding Information
  • Cookies for Kids' Cancer, Leukemia Lymphoma Society, Shaw Foundation, California Cancer League
  • Deutsche Krebshilfe
  • Else Kröner-Fresenius-Stiftung
  • U.S. Department of Health & Human Services | National Institutes of Health
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
  • Alex's Lemonade Stand Foundation for Childhood Cancer

This publication has 82 references indexed in Scilit: